AnnPartridgeMDMPH

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Professor of Medicine, Harvard Medical School; Vice Chair of Medical Oncology, Dana-Farber Cancer Institute

Join to view full profile

Dr. Partridge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Partridge's full profile

Already have an account?

Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1998
Weill Cornell MedicineClass of 1995

Certifications & Licensure

MA State Medical License 1998 - 2026
PA State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com

Clinical Trials

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 3
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
The Young Women's Breast Cancer Study Start of enrollment: 2006 Nov 01
Active, not recruiting
Pilot Study for Young Women's Intervention Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Not Applicable
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors Start of enrollment: 2015 Aug 03
Completed
Not Applicable
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) Start of enrollment: 2017 Feb 20
Active, not recruiting
Not Applicable
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions Start of enrollment: 2017 Dec 01
Active, not recruiting
Not Applicable
Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot Start of enrollment: 2019 May 23
Completed
Not Applicable
YES Study - Newly Diagnosed/Metastatic Intervention Start of enrollment: 2020 Sep 16
Recruiting
Not Applicable
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study Start of enrollment: 2022 Oct 23
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.
Ann H Partridge, Terry Hyslop, Shoshana M Rosenberg, Antonia V Bennett, Sarah Drier
JAMA Oncology. 2024-12-12
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Marc D Ryser, Anna Weiss
JAMA. 2024-12-12
Effects of Adjuvant Endocrine Therapy-Specific Perceptions on Response to a Behavioral Intervention for Adjuvant Endocrine Therapy Adherence in Patients With Breast Ca...
Kelcie D Willis, Emily A Walsh, Laura E Dunderdale, Kathryn Post, Nora Horick
JCO Oncology Practice. 2024-12-01

Journal Articles

Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-Term Counseling and Medication Advice on Smoking Abstinence in Patients Recentl...
Jennifer S Temel, Ann H Partridge, JAMA
Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology

Lectures

POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (B...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Approach to the long-term survivor of breast cancer
Partridge AH, Ruddy KJ
http://www.uptodate.com/contents/approach-to-the-long-term-survivor-of-breast-cancer
UpToDate, Wolters Kluwer Health - 2013-03-29

Press Mentions

“Extremely Provocative” Data Suggest Some Patients with DCIS Can Skip TreatmentDecember 16th, 2024
Is It Safe to Avoid Certain Surgeries During Early Breast Cancer Treatment ?December 13th, 2024
‘Watch and Wait’ Approach Might Be Best for Early DCIS Breast CancersDecember 13th, 2024
Join now to see all